News of Note

Viloxazine (Qelbree): A Faster Strattera?

Topics: ADHD Attention Deficit Hyperactivity Disorder | ADHD-RS-5 | CGI | Clinical Global Impressions | Post-hoc Analysis ADHD Rating Scale-5 | Qelbree | Viloxazine | Weiss Functional Impairment Rating Scale-Parent (WFIRS-P)

On April 2 viloxazine, brand name Qelbree, received an FDA indication for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents ages 6–17 years. Viloxazine is a norepinephrine reuptake inhibitor, similar to atomoxetine (Strattera), which was approved in 2008. Atomoxetine, while approved for ADHD, has some disadva

Read More
Research Update

Viloxazine for ADHD

Topics: ADHD | Atomoxetine | Attention Deficit Hyperactivity Disorder | Qelbree | Research Update | Viloxazine

Review of: Nasser A et al, Int J Clin Pract 2021;75(8):e14330 Study type: Meta-analysis of randomized controlled trials Viloxazine (Qelbree) just got FDA approval in 2021 for the treatment of ADHD in children and adolescents, and the FDA is reviewing data in adult ADHD. Viloxazine has a long history of use as an antidepressant in Europe. Like atomoxet

Read More